5.95
Wave Life Sciences Ltd stock is traded at $5.95, with a volume of 2.41M.
It is down -4.80% in the last 24 hours and up +1.36% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$6.25
Open:
$6.2
24h Volume:
2.41M
Relative Volume:
0.65
Market Cap:
$1.14B
Revenue:
$71.80M
Net Income/Loss:
$-183.59M
P/E Ratio:
-5.6436
EPS:
-1.0543
Net Cash Flow:
$-186.52M
1W Performance:
-5.85%
1M Performance:
+1.36%
6M Performance:
-58.16%
1Y Performance:
-22.73%
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd
|
5.95 | 1.20B | 71.80M | -183.59M | -186.52M | -1.0543 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
WVE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trading the Move, Not the Narrative: (WVE) Edition - Stock Traders Daily
WVE Stock Edges Up After Positive Early Data For Rare Disease Drug - Stocktwits
WVE Technical Analysis & Stock Price Forecast - Intellectia AI
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Has Wave Life Sciences (WVE) Fallen Far Enough To Look Fairly Valued? - Sahm
Wave Life Sciences (WVE) Jefferies London Healthcare Conference 2025 Summary - Quartr
Wave Life Sciences court hearing set for July 14 on redomiciliation - Investing.com
Wave Life Sciences court hearing set for July 14 on redomiciliation By Investing.com - Investing.com South Africa
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation - The Manila Times
What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial - simplywall.st
Is Wave Life Sciences (WVE) Undervalued On Its New Obesity Trial Progress? - simplywall.st
Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect? - Yahoo Finance
Jessica Chen - White & Case LLP
(WVE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial - Insider Monkey
Price to earnings forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
7 Singapore Companies That Have Listed On Nasdaq And Where They Are Now - DollarsAndSense.sg
Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning? - simplywall.st
Enterprise value to EBITDA forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to sales forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Enterprise value to EBIT forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to book forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView
Price to book forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView
Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation - Stock Titan
We Think Wave Life Sciences (NASDAQ:WVE) Can Afford To Drive Business Growth - Moomoo
Price to earnings forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView
Wave Life Sciences(WVE) Stock Options Chain | Quotes & News - Moomoo
Wave Life Sciences Ltd. Actuals & Estimates (NASDAQ:WVE) - TradingView
WVE Forecast — Price Target — Prediction for 2027 - TradingView
Wave Life Sciences initiates phase 2a obesity trial for WVE-007 By Investing.com - Investing.com Australia
Wave Life Sciences initiates phase 2a obesity trial for WVE-007 - Investing.com UK
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT Trial of WVE-007 for Obesity and Cardiometabolic Diseases - Investing News Network
Wave Life Sciences Ltd. (WVE) stock price, news, quote and history - Yahoo Finance Australia
Wave Life Sciences (WVE) Advances Phase 2a Clinical Trial for WV - GuruFocus
Wave Life Sciences Starts Phase 2 Trial of Obesity Drug - Moomoo
Wave Life Sciences Initiates Phase 2a of INLIGHT Trial of WVE-007 for Obesity, Reporting Sustained Visceral Fat Reduction in Phase 1 Data - Quiver Quantitative
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases - The Manila Times
Wave Life Sciences Announces Initiation of Phase 2a Portion - GlobeNewswire
Price-Driven Insight from (WVE) for Rule-Based Strategy - Stock Traders Daily
The Bull Case For Wave Life Sciences (WVE) Could Change Following A Zacks Earnings-Estimate Upgrade - simplywall.st
WAVE LIFE SCIENCES LTD (WVE) Stock Chart - ChartMill
WAVE Life Sciences Ltd (WVE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
WAVE Life Sciences Ltd (WVE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WAVE Life Sciences Ltd (WVE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
WAVE Life Sciences Ltd (WVE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Wave Life Sciences Ltd Stock (WVE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):